key: cord-0710049-d8w9vxvu
authors: Omland, Torbjørn; Mills, Nicholas L; Mueller, Christian
title: Cardiovascular biomarkers in COVID-19
date: 2021-06-14
journal: Eur Heart J Acute Cardiovasc Care
DOI: 10.1093/ehjacc/zuab037
sha: 7ba00b2251149120aa46399506af5d1345fe1af5
doc_id: 710049
cord_uid: d8w9vxvu

nan

non-survivors. 2 Notably, the range of myocardial injury in COVID-19 is wide, and most patients demonstrate lower levels than commonly observed in acute myocardial infarction. A variety of mechanisms may contribute to myocardial injury in COVID-19 (Graphical Abstract). 3 In addition to pre-existing chronic myocardial injury, these include direct viral injury to the myocardium, i.e. viral myocarditis, and acute myocardial infarction. However, these complications are considered to be relatively rare in COVID-19. COVID-19 may also be associated with a pronounced pro-inflammatory state reflected in increased levels of C-reactive protein and IL6, sometimes alluded to as a cytokine storm, which may also cause myocardial injury reflected in rise in cardiac troponin levels. Biomarkers that provide information from different pathophysiological axes, such as growth differentiation factor 15 (GDF-15), may provide particularly strong prognostic information. 4 COVID-19 is also associated with a prothrombotic state. As a result, platelet and clotting factor consumption is reflected in a lower platelet count and increased D-dimer. Direct viral effects in the bone marrow and interactions with platelets, may also contribute to thrombocytopenia.

Although biomarker results always must be seen in a clinical context and cardiovascular biomarker patterns in patients hospitalized with COVID-19 resemble those obtained in studies for pneumonia and ARDS in general, the data accumulated suggest that biomarker assessment may provide information that can assist in the evaluation of disease stage, in the initial triage and patient disposition in the hospital, in determining the need for patient monitoring and need cardiac imaging, as well as short and long-term prognostic assessment. 2, 5 Cardiac troponin, cardiac natriuretic peptide, and D-dimer should be measured on admission in all patients with suspected COVID-19 presenting with chest discomfort or dyspnoea. The results may assist in early disease staging and initial triage. Comparison with pre-COVID measurements, if available, is helpful to determine the relative contribution of pre-existing chronic vs. acute injury and dysfunction.

Serial measurement of cardiac troponin, cardiac natriuretic peptide, and D-dimer during hospitalization may provide information concerning short-and long-term risk and guide the need for cardiac imaging. Serial measurements may be particularly helpful in those in whom risk stratum and disease stage is uncertain.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Cardiac troponin for assessment of myocardial injury in COVID-19: JACC review topic of the week

Cardiovascular biomarkers in patients with COVID-19

Growth differentiation factor 15 provides prognostic information superior to established cardiovascular and inflammatory biomarkers in unselected patients hospitalized with COVID-19

High-sensitivity cardiac troponin can be an ally in the fight against COVID-19

Diagnostics, Roche Diagnostics and Bayer and has received research support from Abbott Diagnostics, Novartis, Roche Diagnostics, Singulex, and SomaLogic through Akershus University Hospital and speaker's or consulting honoraria from Roche Diagnostics, Siemens Healthineers, and CardiNor. T.O. is also listed as an inventor on a patent application titled, 'GDF-15 for Predicting the Disease Severity of a Patient With COVID-19'. N.L.M. reports research grants awarded to the University of Edinburgh from Abbott Diagnostics and Siemens Healthineers outside the submitted work, and honoraria from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics and LumiraDx. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the University Hospital Basel, the University of Basel; Abbott, Beckman Coulter, Brahms, Idorsia, Novartis, Ortho Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec outside the submitted work, as well as speaker honoraria/consulting honoraria from Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, BMS, Novartis, Osler, Roche, and Sanofi paid to the institution.